# Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

> **NCT04194684** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 108 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** nab-paclitaxel

## Key facts

- **NCT ID:** NCT04194684
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-28
- **Primary completion:** 2022-12-28
- **Final completion:** 2023-01-30
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2019-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04194684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04194684, "Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04194684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*